‘In March 2015, IMI launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.
“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview
Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective. The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.